Vaccination with DEXsOVA-CTLA-4 increased the migration of CD4+ and CD8+ T cells to the tumor site and elevated the ratio of CTLs/Tregs in the microenvironment of B16 melanoma tumor model after 12 days (78). This evidence concerns the gene CD4 and neoplasm.